Search
Kymera Therapeutics Inc
KYMRAdd to Watchlist
85.660USD
+2.110+2.53%
Close 05/13, 16:00（ET）Quotes delayed by 15 min
7.04BMarket Cap
LossP/E TTM
More Details of Kymera Therapeutics Inc Company
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
Kymera Therapeutics Inc Info
Ticker SymbolKYMR
Company nameKymera Therapeutics Inc
IPO dateAug 21, 2020
CEOMainolfi (Nello)
Number of employees188
Security typeOrdinary Share
Fiscal year-endAug 21
Address500 North Beacon Street, 4Th Floor
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone18572855314
Websitehttps://www.kymeratx.com/
Ticker SymbolKYMR
IPO dateAug 21, 2020
CEOMainolfi (Nello)
Company Executives of Kymera Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
666.20K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
71.36K
+19.43%
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
9.81K
--
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
3.39K
-268.84%
Dr. Pamela Esposito, Ph.D.
Dr. Pamela Esposito, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
--
--
Ms. Elena H. Ridloff
Ms. Elena H. Ridloff
Independent Director
Independent Director
--
--
Mr. Bruce N. Jacobs
Mr. Bruce N. Jacobs
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
666.20K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
71.36K
+19.43%
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
9.81K
--
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
3.39K
-268.84%
Dr. Pamela Esposito, Ph.D.
Dr. Pamela Esposito, Ph.D.
Independent Director
Independent Director
--
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
39.21M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: 22 hours ago
Updated: 22 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
10.52%
Fidelity Management & Research Company LLC
10.47%
Avoro Capital Advisors LLC
9.09%
T. Rowe Price Associates, Inc.
7.41%
BVF Partners L.P.
6.69%
Other
55.82%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
10.52%
Fidelity Management & Research Company LLC
10.47%
Avoro Capital Advisors LLC
9.09%
T. Rowe Price Associates, Inc.
7.41%
BVF Partners L.P.
6.69%
Other
55.82%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.54%
Investment Advisor/Hedge Fund
28.92%
Hedge Fund
25.81%
Venture Capital
6.19%
Research Firm
1.40%
Individual Investor
1.14%
Corporation
0.94%
Private Equity
0.43%
Bank and Trust
0.43%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
505
96.67M
117.53%
+10.35M
2025Q4
463
86.46M
108.36%
+3.09M
2025Q3
423
80.49M
111.88%
+1.59M
2025Q2
394
76.16M
108.56%
+417.04K
2025Q1
408
74.79M
106.76%
-4.90M
2024Q4
392
73.17M
112.73%
-3.17M
2024Q3
379
71.17M
110.57%
-5.78M
2024Q2
360
69.86M
113.52%
-7.55M
2024Q1
364
70.22M
115.13%
-982.70K
2023Q4
350
63.05M
113.62%
-5.46M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
8.66M
10.6%
+2.01M
+30.16%
Dec 31, 2025
Fidelity Management & Research Company LLC
8.61M
10.55%
+2.73M
+46.44%
Dec 31, 2025
Avoro Capital Advisors LLC
7.47M
9.16%
+1.12M
+17.71%
Dec 31, 2025
T. Rowe Price Associates, Inc.
6.09M
7.46%
+1.06M
+20.99%
Dec 31, 2025
BVF Partners L.P.
5.50M
6.74%
--
--
Dec 31, 2025
Atlas Venture
4.66M
5.71%
-236.59K
-4.83%
Dec 31, 2025
Wellington Management Company, LLP
4.41M
5.41%
-782.76K
-15.07%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
4.25M
5.21%
+529.10K
+14.21%
Dec 31, 2025
Invus Public Equities Advisors, LLC
3.29M
4.03%
-141.32K
-4.12%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Clough Hedged Equity ETF
2.42%
Invesco Dorsey Wright Healthcare Momentum ETF
1.41%
Harbor Human Capital Factor US Small Cap ETF
1.31%
State Street SPDR S&P Biotech ETF
1.27%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
Direxion Daily S&P Biotech Bull 3X Shares
0.63%
First Trust Multi-Manager Small Cap Opportunities ETF
0.61%
ProShares Ultra Nasdaq Biotechnology
0.59%
Invesco Nasdaq Biotechnology ETF
0.43%
First Trust Small Cap Growth AlphaDEX Fund
0.35%
View more
Clough Hedged Equity ETF
Proportion2.42%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.41%
Harbor Human Capital Factor US Small Cap ETF
Proportion1.31%
State Street SPDR S&P Biotech ETF
Proportion1.27%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.89%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.63%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.61%
ProShares Ultra Nasdaq Biotechnology
Proportion0.59%
Invesco Nasdaq Biotechnology ETF
Proportion0.43%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.35%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
